Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.
Fingolimod
Macular volume
Multiple sclerosis
Optical coherence tomography
Safety
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
13
08
2020
accepted:
05
10
2020
pubmed:
10
10
2020
medline:
15
5
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment. The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting. Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years. The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up. Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS.
Sections du résumé
BACKGROUND
BACKGROUND
Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment.
OBJECTIVES
OBJECTIVE
The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting.
METHODS
METHODS
Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years.
RESULTS
RESULTS
The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up.
CONCLUSIONS
CONCLUSIONS
Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS.
Identifiants
pubmed: 33033898
doi: 10.1007/s10072-020-04802-x
pii: 10.1007/s10072-020-04802-x
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
731-733Références
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415. https://doi.org/10.1056/NEJMoa0907839
doi: 10.1056/NEJMoa0907839
pubmed: 20089954
Jain N, Bhatti MT (2012) Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78:672–680
doi: 10.1212/WNL.0b013e318248deea
Abramoff MD, Garvin MK, Sonka M (2010) Retinal imaging and image analysis. IEEE Rev Biomed Eng 3:169–208
doi: 10.1109/RBME.2010.2084567
Nolan R, Gelfand JM, Green AJ (2013) Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 80:139–144. https://doi.org/10.1212/WNL.0b013e31827b9132
doi: 10.1212/WNL.0b013e31827b9132
pubmed: 23223539
pmcid: 3589191
Nørgaard TL, Andersen CU, Hilt C, Andersen CU (2020) Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod. Basic Clin Pharmacol Toxicol 126:492–497. https://doi.org/10.1111/bcpt.13381
doi: 10.1111/bcpt.13381
pubmed: 31880065
Gilenya | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya . Accessed 22 Jun 2020
Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One 7:e34823. https://doi.org/10.1371/journal.pone.0034823
doi: 10.1371/journal.pone.0034823
pubmed: 22536333
pmcid: 3334941
Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, Saba J, Vogel SM, Malik AB, Mehta D (2008) Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res 103:1164–1172. https://doi.org/10.1161/01.RES.0000338501.84810.51
doi: 10.1161/01.RES.0000338501.84810.51
pubmed: 18849324
pmcid: 2708004
Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401. https://doi.org/10.1056/NEJMoa0909494
doi: 10.1056/NEJMoa0909494
pubmed: 20089952
Fruschelli M, Capozzoli M, Gelmi MC, Masi G, Annunziata P (2019) Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing–remitting multiple sclerosis. Int Ophthalmol 39:777–781. https://doi.org/10.1007/s10792-018-0870-x
doi: 10.1007/s10792-018-0870-x
pubmed: 29500696